## Monica McNeal

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4207957/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Influenza clinical testing and oseltamivir treatment in hospitalized children with acute respiratory illness, 2015–2016. Influenza and Other Respiratory Viruses, 2022, 16, 289-297.	3.4	3
2	Lethal Pediatric Cerebral Vasculitis Triggered by Severe Acute Respiratory Syndrome Coronavirus 2. Pediatric Neurology, 2022, 127, 1-5.	2.1	24
3	Immunogenicity of a third scheduled dose of Rotarix in Australian Indigenous infants: a phase IV, double-blind, randomised, placebo-controlled clinical trial. Journal of Infectious Diseases, 2022, , .	4.0	4
4	Vaccine Effectiveness Against Influenza Hospitalization and Emergency Department Visits in 2 A(H3N2) Dominant Influenza Seasons Among Children <18 Years Old—New Vaccine Surveillance Network 2016–2017 and 2017–2018. Journal of Infectious Diseases, 2022, 226, 91-96.	4.0	6
5	Association of Anti-Rotavirus IgA Seroconversion with Growth, Environmental Enteric Dysfunction and Enteropathogens in Rural Pakistani Infants. Vaccine, 2022, 40, 3444-3451.	3.8	1
6	Vaccine Effectiveness Against Influenza Hospitalization Among Children in the United States, 2015–2016. Journal of the Pediatric Infectious Diseases Society, 2021, 10, 75-82.	1.3	19
7	A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nature Medicine, 2021, 27, 106-114.	30.7	204
8	Safety and immunogenicity of an intranasal sendai virus-based vaccine for human parainfluenza virus type I and respiratory syncytial virus (SeVRSV) in adults. Human Vaccines and Immunotherapeutics, 2021, 17, 554-559.	3.3	19
9	Effect of Vaccination on Preventing Influenza-Associated Hospitalizations Among Children During a Severe Season Associated With B/Victoria Viruses, 2019–2020. Clinical Infectious Diseases, 2021, 73, e947-e954.	5.8	15
10	Pediatric Respiratory and Enteric Virus Acquisition and Immunogenesis in US Mothers and Children Aged 0-2: PREVAIL Cohort Study. JMIR Research Protocols, 2021, 10, e22222.	1.0	11
11	Acute Respiratory Illnesses in Children in the SARS-CoV-2 Pandemic: Prospective Multicenter Study. Pediatrics, 2021, 148, .	2.1	72
12	Rotavirus vaccine efficacy up to 2 years of age and against diverse circulating rotavirus strains in Niger: Extended follow-up of a randomized controlled trial. PLoS Medicine, 2021, 18, e1003655.	8.4	10
13	Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from August to December 2020. PLoS ONE, 2021, 16, e0254667.	2.5	4
14	Immunogenicity of an oral rotavirus vaccine administered with prenatal nutritional support in Niger: A cluster randomized clinical trial. PLoS Medicine, 2021, 18, e1003720.	8.4	12
15	High Mobility Group Box 1 Release by Cholangiocytes Governs Biliary Atresia Pathogenesis and Correlates With Increases in Afflicted Infants. Hepatology, 2021, 74, 864-878.	7.3	20
16	Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: Results from a phase 2b randomized, placebo-controlled challenge study in adults. EClinicalMedicine, 2021, 39, 101076.	7.1	37
17	Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants. Vaccine, 2021, 39, 5513-5523.	3.8	16
18	Persistence of Maternal Anti-Rotavirus Immunoglobulin G in the Post–Rotavirus Vaccine Era. Journal of Infectious Diseases, 2021, 224, 133-136.	4.0	2

#	Article	IF	CITATIONS
19	Antibody in Lymphocyte Supernatant (ALS) responses after oral vaccination with live Shigella sonnei vaccine candidates WRSs2 and WRSs3 and correlation with serum antibodies, ASCs, fecal IgA and shedding. PLoS ONE, 2021, 16, e0259361.	2.5	4
20	T-Bet Deficiency Attenuates Bile Duct Injury in Experimental Biliary Atresia. Cells, 2021, 10, 3461.	4.1	6
21	Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial. Lancet Infectious Diseases, The, 2020, 20, 80-91.	9.1	103
22	Cytomegalovirus Genetic Diversity Following Primary Infection. Journal of Infectious Diseases, 2020, 221, 715-720.	4.0	13
23	Rotavirus Reassortant–Induced Murine Model of Liver Fibrosis Parallels Human Biliary Atresia. Hepatology, 2020, 71, 1316-1330.	7.3	12
24	Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G. MSphere, 2020, 5, .	2.9	25
25	Vaccine Effectiveness Against Pediatric Influenza Hospitalizations and Emergency Visits. Pediatrics, 2020, 146, e20201368.	2.1	21
26	Establishment of a Controlled Human Infection Model with a Lyophilized Strain of Shigella sonnei 53G. MSphere, 2020, 5, .	2.9	13
27	Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2020, 20, 851-863.	9.1	51
28	Continued Evidence of the Impact of Rotavirus Vaccine in Children Less Than 3 Years of Age From the United States New Vaccine Surveillance Network: A Multisite Active Surveillance Program, 2006–2016. Clinical Infectious Diseases, 2020, 71, e421-e429.	5.8	8
29	Association of Rotavirus Vaccination With Inpatient and Emergency Department Visits Among Children Seeking Care for Acute Gastroenteritis, 2010-2016. JAMA Network Open, 2019, 2, e1912242.	5.9	18
30	Human VP8* mAbs neutralize rotavirus selectively in human intestinal epithelial cells. Journal of Clinical Investigation, 2019, 129, 3839-3851.	8.2	32
31	Enterovirus D68–Associated Acute Respiratory Illness — New Vaccine Surveillance Network, United States, July–October, 2017 and 2018. Morbidity and Mortality Weekly Report, 2019, 68, 277-280.	15.1	48
32	Open-Label Pilot Study to Compare the Safety and Immunogenicity of Pentavalent Rotavirus Vaccine (RV5) Administered on an Early Alternative Dosing Schedule with Those of RV5 Administered on the Recommended Standard Schedule. Journal of the Pediatric Infectious Diseases Society, 2018, 7, 82-85.	1.3	7
33	Randomized trial comparing the safety and antibody responses to live attenuated versus inactivated influenza vaccine when administered to breastfeeding women. Vaccine, 2018, 36, 4663-4671.	3.8	15
34	A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei. Vaccine, 2018, 36, 4880-4889.	3.8	30
35	Year-round influenza immunisation during pregnancy in Nepal: a phase 4, randomised, placebo-controlled trial. Lancet Infectious Diseases, The, 2017, 17, 981-989.	9.1	185
36	A Point Mutation in the Rhesus Rotavirus VP4 Protein Generated through a Rotavirus Reverse Genetics System Attenuates Biliary Atresia in the Murine Model. Journal of Virology, 2017, 91, .	3.4	11

#	Article	IF	CITATIONS
37	Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet Infectious Diseases, The, 2017, 17, 843-853.	9.1	109
38	Enterovirus D68 Infection Among Children With Medically Attended Acute Respiratory Illness, Cincinnati, Ohio, July–October 2014. Clinical Infectious Diseases, 2017, 65, 315-323.	5.8	15
39	The SRL peptide of rhesus rotavirus VP4 protein governs cholangiocyte infection and the murine model of biliary atresia. Hepatology, 2017, 65, 1278-1292.	7.3	13
40	Rhesus rotavirus VP6 regulates ERK-dependent calcium influx in cholangiocytes. Virology, 2016, 499, 185-195.	2.4	11
41	Noninterference of Rotavirus Vaccine With Measles-Rubella Vaccine at 9 Months of Age and Improvements in Antirotavirus Immunity: A Randomized Trial. Journal of Infectious Diseases, 2016, 213, 1686-1693.	4.0	44
42	Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules. Pediatrics, 2016, 137, e20152603.	2.1	28
43	Safety and immunogenicity of a parenterally administered rotavirus VP8 subunit vaccine in healthy adults. Vaccine, 2015, 33, 3766-3772.	3.8	48
44	Multiplex real-time RT-PCR for the simultaneous detection and quantification of GI, GII and GIV noroviruses. Journal of Virological Methods, 2015, 223, 109-114.	2.1	19
45	Rhesus rotavirus VP4 sequence-specific activation of mononuclear cells is associated with cholangiopathy in murine biliary atresia. American Journal of Physiology - Renal Physiology, 2015, 309, G466-G474.	3.4	14
46	Epidemiologic Association Between <i>FUT2</i> Secretor Status and Severe Rotavirus Gastroenteritis in Children in the United States. JAMA Pediatrics, 2015, 169, 1040.	6.2	112
47	Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012–2013. Clinical Infectious Diseases, 2015, 61, 1792-1799.	5.8	78
48	Impact of Different Dosing Schedules on the Immunogenicity of the Human Rotavirus Vaccine in Infants in Pakistan: A Randomized Trial. Journal of Infectious Diseases, 2014, 210, 1772-1779.	4.0	41
49	Branched-linear and agglomerate protein polymers as vaccine platforms. Biomaterials, 2014, 35, 8427-8438.	11.4	18
50	Rotaviruses. , 2014, , 713-732.		3
51	Effectiveness of Pentavalent and Monovalent Rotavirus Vaccines in Concurrent Use Among US Children <5 Years of Age, 2009–2011. Clinical Infectious Diseases, 2013, 57, 13-20.	5.8	146
52	Role of myeloid differentiation factor 88 in Rhesus rotavirus-induced biliary atresia. Journal of Surgical Research, 2013, 184, 322-329.	1.6	5
53	Comparison of 2 Assays for Diagnosing Rotavirus and Evaluating Vaccine Effectiveness in Children with Gastroenteritis. Emerging Infectious Diseases, 2013, 19, 1245-1252.	4.3	46
54	Rotavirus Replication in the Cholangiocyte Mediates the Temporal Dependence of Murine Biliary Atresia. PLoS ONE, 2013, 8, e69069.	2.5	29

#	Article	IF	CITATIONS
55	Predicting Susceptibility to Norovirus GII.4 by Use of a Challenge Model Involving Humans. Journal of Infectious Diseases, 2012, 206, 1386-1393.	4.0	124
56	Rotavirus infection of human cholangiocytes parallels the murine model of biliary atresia. Journal of Surgical Research, 2012, 177, 275-281.	1.6	33
57	Norovirus P Particle, a Novel Platform for Vaccine Development and Antibody Production. Journal of Virology, 2011, 85, 753-764.	3.4	135
58	A candidate dual vaccine against influenza and noroviruses. Vaccine, 2011, 29, 7670-7677.	3.8	57
59	Norovirus P Particle as a Platform for Antigen Presentation. Procedia in Vaccinology, 2011, 4, 19-26.	0.4	23
60	INCIDENCE OF INFLUENZA VIRUS INFECTION IN EARLY INFANCY. Pediatric Infectious Disease Journal, 2011, 30, 170-173.	2.0	27
61	The Rhesus Rotavirus Gene Encoding VP4 Is a Major Determinant in the Pathogenesis of Biliary Atresia in Newborn Mice. Journal of Virology, 2011, 85, 9069-9077.	3.4	32
62	Estimating the Rotavirus Hospitalization Disease Burden and Trends, Using Capture-recapture Methods. Pediatric Infectious Disease Journal, 2010, 29, 1083-1087.	2.0	18
63	Simian Rotaviruses Possess Divergent Gene Constellations That Originated from Interspecies Transmission and Reassortment. Journal of Virology, 2010, 84, 2013-2026.	3.4	60
64	The adjuvant CLDC increases protection of a herpes simplex type 2 glycoprotein D vaccine in guinea pigs. Vaccine, 2010, 28, 3748-3753.	3.8	37
65	Rotavirus. , 2009, , 645-669.		0
66	Cholangiocyte expression of α <sub>2</sub> 1² <sub>1</sub> -integrin confers susceptibility to rotavirus-induced experimental biliary atresia. American Journal of Physiology - Renal Physiology, 2008, 295, G16-G26.	3.4	44
67	Effect of Rotavirus Strain on the Murine Model of Biliary Atresia. Journal of Virology, 2007, 81, 1671-1679.	3.4	68
68	Effector Role of Neonatal Hepatic CD8+ Lymphocytes in Epithelial Injury and Autoimmunity in Experimental Biliary Atresia. Gastroenterology, 2007, 133, 268-277.	1.3	103
69	MAPK signaling contributes to rotaviral-induced cholangiocyte injury and viral replication. Surgery, 2007, 142, 192-201.	1.9	31
70	Seroepidemiologic Evaluation of Antibodies to Rotavirus as Correlates of the Risk of Clinically Significant Rotavirus Diarrhea in Rural Bangladesh. Journal of Infectious Diseases, 1992, 165, 161-165.	4.0	57
71	Ultrastructure of cultured hepatocytes from fat- and cholesterol-fed rats. Vigiliae Christianae, 1982, 41, 95-106.	0.1	4